Montreal Classification for Inflammatory Bowel Disease (IBD)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Crohn's Disease Classification—
- Ulcerative Colitis Classification—
The Montreal Classification for Inflammatory Bowel Disease (IBD) calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include disease type. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Classifies phenotype and severity of Crohn's disease and ulcerative colitis to guide treatment decisions and predict disease course.
Clinical Indication
The Montreal Classification for Inflammatory Bowel Disease (IBD) is indicated for bedside clinical practice to support Classifies phenotype and severity of Crohn's disease and ulcerative colitis to guide treatment decisions and predict disease course.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy. Guideline pearl: Helps predict prognosis and guide treatment strategies.
For Crohn's Disease: A[age] + L[location] + B[behavior] + p[perianal]. For Ulcerative Colitis: A[age] + E[extent] + S[severity]. Age: A1 (<17y), A2 (17-40y), A3 (>40y).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| disease_type | string | Yes | Type of inflammatory bowel disease |
| age_at_diagnosis | integer | Yes | Age at diagnosis in years for Montreal Age classification(years) |
| crohns_location | string | No | Location of Crohn's disease (L1-L4) - only for Crohn's disease |
| crohns_behavior | string | No | Behavior pattern of Crohn's disease (B1-B3) - only for Crohn's disease |
| perianal_disease | string | No | Presence of perianal disease modifier (p) - only for Crohn's disease |
| uc_extent | string | No | Extent of ulcerative colitis (E1-E3) - only for ulcerative colitis |
| uc_severity | string | No | Severity of ulcerative colitis (S0-S3) - only for ulcerative colitis |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Crohn's Disease Classification | Age + Location + Behavior + Perianal modifier |
| — | Ulcerative Colitis Classification | Age + Extent + Severity |
Evidence-Based References (EBM)
- Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A. doi: 10.1155/2005/269076.DOI: 10.1155/2005/269076
- Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-53. doi: 10.1136/gut.2005.082909.DOI: 10.1136/gut.2005.082909
- Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139(4):1147-55. doi: 10.1053/j.gastro.2010.06.070.DOI: 10.1053/j.gastro.2010.06.070